Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
• Demonstrate superior analgesic efficacy of tanezumab 10 mg and 5 mg administered IV every 8 weeks compared to placebo at Week 16. • Demonstrate non-inferiority and, if warranted, superior analgesic efficacy of tanezumab 10 mg and 5 mg administered IV every 8 weeks compared to oxycodone HCl controlled release (CR) tablets (Oxycontin) 10-40 mg every 12 hours (q12h) at Week 16.
Inclusion criteria
- osteoarthritis of the knee and hip